US-based biotechnology company Aldeyra Therapeutics reported positive clinical trial results of topical dermatologic NS2 to treat Sjögren-Larsson Syndrome (SLS).

The NS2 is developed as an aldehyde trap, specifically targeting and reducing levels of toxic aldehydes that are toxic, as well as pro-inflammatory agents of numerous diseases.

The randomised, parallel-group, double-blind, vehicle-controlled, multi-centre trial involved 12 patients suffering from moderate to severe ichthyosis, which is a dermal manifestation of SLS.

The patients were randomised to receive NS2 1.0% dermatologic formulation or vehicle formulation on a once-daily regimen applied on 4in x 10in area of skin for two months.

"I am excited about these results, and I am particularly excited for SLS patients and their caregivers."

Both the patients and investigators were blinded to treatment group and ichthyosis was examined by a blinded central review of digital photographs.

The clinical exam was reviewed on a blinded basis by the Ichthyosis Severity Score, which comprises assessments of global impression, scaling, erythema (redness), lichenification (thickness) and excoriation (abrasion).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Additionally, dermal tissue from subjects was examined for biomarkers relevant to fatty aldehyde dehydrogenase deficiency.

Results suggested that NS2 has reduced severity of ichthyosis on a consistent basis.

Exhibiting a tolerable profile, NS2 was also noted to have reduced cholesterol level in the skin of SLS patients.

Principal investigator of trial Dr William Rizzo said: "The data from this trial suggests that NS2, when applied topically to the skin, has the potential to help patients suffering from SLS by lowering toxic aldehyde levels and preventing the dermal dysfunction that causes ichthyosis.

“I am excited about these results, and I am particularly excited for SLS patients and their caregivers."

SLS is a rarely occurring inborn error of aldehyde metabolism caused due to mutations in fatty acid aldehyde dehydrogenase, leading to elevated toxic fatty aldehyde levels.

NS2 reduces the aldehyde levels, thereby inhibiting the inflammation of the toxins to trigger the disease.